AGN Stock Overview
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Argenica Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.56 |
| 52 Week High | AU$0.75 |
| 52 Week Low | AU$0.29 |
| Beta | 0.69 |
| 1 Month Change | -4.24% |
| 3 Month Change | -10.32% |
| 1 Year Change | 28.41% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 117.31% |
Recent News & Updates
Recent updates
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth
Jan 12
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business
Jul 20Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business
Apr 20We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Nov 30Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans
Aug 12Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation
Apr 29Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation
Dec 30We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Sep 16Shareholder Returns
| AGN | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -0.9% | -3.3% | 0.4% |
| 1Y | 28.4% | 29.3% | 6.0% |
Return vs Industry: AGN matched the Australian Pharmaceuticals industry which returned 29.3% over the past year.
Return vs Market: AGN exceeded the Australian Market which returned 6% over the past year.
Price Volatility
| AGN volatility | |
|---|---|
| AGN Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: AGN has not had significant price volatility in the past 3 months.
Volatility Over Time: AGN's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Liz Dallimore | argenica.com.au |
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Argenica Therapeutics Limited Fundamentals Summary
| AGN fundamental statistics | |
|---|---|
| Market cap | AU$68.78m |
| Earnings (TTM) | -AU$4.67m |
| Revenue (TTM) | AU$2.72m |
25.5x
P/S Ratio-14.9x
P/E RatioIs AGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGN income statement (TTM) | |
|---|---|
| Revenue | AU$2.72m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.72m |
| Other Expenses | AU$7.40m |
| Earnings | -AU$4.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.038 |
| Gross Margin | 100.00% |
| Net Profit Margin | -171.52% |
| Debt/Equity Ratio | 0% |
How did AGN perform over the long term?
See historical performance and comparison